RxDoctor Payments Data

Rishi Patel, DO

Family Medicine · St Petersburg, FLNPI 1518313170

Payments from drug & device makers

$5,477in general payments, 2019–2025

Across 180 payments — averaging $30.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$800
  • AbbVie$760
  • Lilly USA, LLC$728
  • Abbott$320
  • Amgen$304
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$5,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,477 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$266,290
Medicare patients
550
Services billed
2,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$67,397
EliquisApixaban49$48,683
FarxigaDapagliflozin Propanediol46$42,086
MounjaroTirzepatide14$17,926
RybelsusSemaglutide17$16,385
Breo ElliptaFluticasone/Vilanterol21$11,598
JanuviaSitagliptin Phosphate13$9,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,466
Hydrocortisone37$8,594
Sucralfate16$8,335
Tresiba Flextouch U-100Insulin Degludec14$7,596
Ondansetron Hcl12$6,134
Dexlansoprazole DrDexlansoprazole29$4,877
Diclofenac Sodium55$4,433
Albuterol Sulfate HfaAlbuterol Sulfate92$2,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$800$83,78367 claims
PfizerEliquis$148$48,68349 claims
AstraZenecaFarxiga$1,132$42,08646 claims
GSKBreo Ellipta, Trelegy Ellipta$51$21,06434 claims
Lilly USA, LLCMounjaro$728$17,92614 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,734149 claims
AbbVieSynthroid$760$1,57625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →